

**Response to Office Action**  
**USSN 09/892,308 filed June 27, 2001**

**Annexure 1 - Claims Rewritten to Show Amendments**

1. (Canceled)

2.(Previously Amended) A method of preventing toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD to a cell comprising treating said cell with a compound wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

Claims 3 -16 (Canceled)

17.(Previously Amended) A method of treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD, comprising administering a composition comprising a pharmacologically effective amount of a compound, wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

Claims 18 - 34 (Canceled)

35.(Amended) The method of Claim 17, wherein inhibiting treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E toxicity comprises inhibiting binding of apolipoprotein E or fragments of apolipoprotein E to a cell.

36.(Original) The method of Claim 35, wherein the fragments of apolipoprotein E comprises residues 141-147 of apolipoprotein E.

37.(Amended) The method of Claim 17, wherein inhibiting treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E toxicity

**Response to Office Action**  
**USSN 09/892,308 filed June 27, 2001**

comprises inhibiting production of a peptide fragment of apolipoprotein E comprising residues 141-147 of apolipoprotein E.

38.(Amended) The method of Claim 17, wherein the condition is selected from the group consisting of Alzheimer's-type senile dementia, a condition associated with cerebral amyloidosis and hyperlipidemia hyperlipidemia.

39.(Original) The method of Claim 17, wherein the condition is selected from the group consisting of coronary heart disease, atherosclerosis, head injury, ischemic stroke, intracerebral hemorrhage, normal pressure hydrocephalus, HIV-associated dementia and HIV-associated peripheral neuropathy.

Claims 40-49 (Canceled)